BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zheng J, Kuk D, Gönen M, Balachandran VP, Kingham TP, Allen PJ, D'Angelica MI, Jarnagin WR, DeMatteo RP. Actual 10-Year Survivors After Resection of Hepatocellular Carcinoma. Ann Surg Oncol 2017;24:1358-66. [PMID: 27921192 DOI: 10.1245/s10434-016-5713-2] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Lin YP, Lin SH, Wang CC, Lin CC, Chen DW, Chuang CH, Huang PY, Hung CH, Yang SY, Cho WR, Chen YS, Tsai MC. Impact of MAFLD on HBV-Related Stage 0/A Hepatocellular Carcinoma after Curative Resection. J Pers Med 2021;11:684. [PMID: 34442328 DOI: 10.3390/jpm11080684] [Reference Citation Analysis]
2 Kim S, Cho CY, Lee D, Song DG, Kim HJ, Jung JW, Kim JE, Park D, Lee H, Um H, Park J, Choi Y, Kim Y, Nam SH, Lee JW. CD133-induced TM4SF5 expression promotes sphere growth via recruitment and blocking of protein tyrosine phosphatase receptor type F (PTPRF). Cancer Lett 2018;438:219-31. [PMID: 30217560 DOI: 10.1016/j.canlet.2018.09.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
3 Solaini L, Cucchetti A, Piccino M, Gardini A, La Barba G, Serenari M, Cescon M, Ercolani G. Critical systematic review on hepatic resection and transarterial chemoembolization for hepatocellular carcinoma. Future Oncol 2019;15:439-49. [PMID: 30620230 DOI: 10.2217/fon-2018-0269] [Reference Citation Analysis]
4 Lin CY, Lin CC, Wang CC, Chen CL, Hu TH, Hung CH, Huang PY, Tsai MC. The ALBI Grade is a Good Predictive Model for Very Late Recurrence in Patients with Hepatocellular Carcinoma Undergoing Primary Resection. World J Surg. 2020;44:247-257. [PMID: 31559485 DOI: 10.1007/s00268-019-05197-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Ng KKC, Cheng NMY, Huang J, Liao M, Chong CCN, Lee KF, Wong J, Cheung SYS, Lok HT, Fung AKY, Wong GLH, Wong VWS, Lai PBS. Development and validation of a novel nomogram predicting 10-year actual survival after curative hepatectomy for hepatocellular carcinoma. Surgeon 2021:S1479-666X(20)30186-4. [PMID: 33423927 DOI: 10.1016/j.surge.2020.11.013] [Reference Citation Analysis]
6 Li L, Situ HJ, Ma WC, Liu X, Wang LL. Decreased DHRS1 expression is a novel predictor of poor survival in patients with hepatocellular carcinoma. Biomark Med 2021;15:1319-31. [PMID: 34498498 DOI: 10.2217/bmm-2021-0041] [Reference Citation Analysis]
7 Liu R, Wang G, Zhang C, Bai D. A prognostic model for hepatocellular carcinoma based on apoptosis-related genes. World J Surg Oncol 2021;19:70. [PMID: 33712023 DOI: 10.1186/s12957-021-02175-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Li B, Xu T, Liu C, Meng G, Sun Y, Qian L, Wang S, Wei J, Yu D, Ding Y. Liver-enriched Genes are Associated with the Prognosis of Patients with Hepatocellular Carcinoma. Sci Rep 2018;8:11197. [PMID: 30046116 DOI: 10.1038/s41598-018-29237-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
9 Zhang L. Single-Cell Profiling Explore the Immunologic Mechanisms of Tumor Relapse in Hepatocellular Carcinoma. Glob Med Genet 2021;8:83-4. [PMID: 34430957 DOI: 10.1055/s-0041-1729545] [Reference Citation Analysis]
10 Li L, Li B, Zhang M. Postoperative adjuvant transarterial chemoembolization improves the prognosis of hepatocellular carcinoma patients with microvascular invasion: a systematic review and meta-analysis. Acta Radiol 2020;61:723-31. [PMID: 31594382 DOI: 10.1177/0284185119878357] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
11 Pelizzaro F, Vitale A, Sartori A, Vieno A, Penzo B, Russo FP, Frigo AC, Giannini EG, Piccinnu M, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Sacco R, Celsa C, Marra F, Mega A, Guarino M, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Olivani A, Masotto A, Coccoli P, Raimondo G, Azzaroli F, Vidili G, Brunetto MR, Trevisani F, Farinati F, On Behalf Of Ita Li Ca Study Group. Surveillance as Determinant of Long-Term Survival in Non-Transplanted Hepatocellular Carcinoma Patients. Cancers (Basel) 2021;13:897. [PMID: 33672751 DOI: 10.3390/cancers13040897] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Horvat N, Nikolovski I, Long N, Gerst S, Zheng J, Pak LM, Simpson A, Zheng J, Capanu M, Jarnagin WR, Mannelli L, Do RKG. Imaging features of hepatocellular carcinoma compared to intrahepatic cholangiocarcinoma and combined tumor on MRI using liver imaging and data system (LI-RADS) version 2014. Abdom Radiol (NY) 2018;43:169-78. [PMID: 28765978 DOI: 10.1007/s00261-017-1261-x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 8.5] [Reference Citation Analysis]
13 Matsushima H, Takami Y, Ryu T, Yoshitomi M, Tateishi M, Wada Y, Saitsu H. Prognosis of Hepatocellular Carcinoma Patients Who Achieved Long-Term Recurrence-Free Survival After Curative Therapy: Impact of the ALBI Grade. J Gastrointest Surg 2018;22:1230-8. [DOI: 10.1007/s11605-018-3745-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
14 Zhao QJ, Zhang J, Xu L, Liu FF. Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma. World J Gastroenterol 2018; 24(30): 3426-3439 [PMID: 30122881 DOI: 10.3748/wjg.v24.i30.3426] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 38] [Article Influence: 9.5] [Reference Citation Analysis]
15 Ryu T, Takami Y, Wada Y, Hara T, Sasaki S, Saitsu H. Actual 10-Year Survival After Surgical Microwave Ablation for Hepatocellular Carcinoma: A Single-Center Experience in Japan. Ann Surg Oncol. 2019;26:4126-4133. [PMID: 31359277 DOI: 10.1245/s10434-019-07646-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
16 Sempokuya T, Wong LL. Ten-year survival and recurrence of hepatocellular cancer. Hepatoma Res 2019;5:38. [PMID: 31701016 DOI: 10.20517/2394-5079.2019.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
17 Tsai MC, Lin CC, Chen DW, Liu YW, Wu YJ, Yen YH, Huang PY, Yao CC, Chuang CH, Hsiao CC. The Role of Protease-Activated Receptor 2 in Hepatocellular Carcinoma after Hepatectomy. Medicina (Kaunas) 2021;57:574. [PMID: 34199695 DOI: 10.3390/medicina57060574] [Reference Citation Analysis]
18 Bagante F, Spolverato G, Weiss M, Alexandrescu S, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, Bauer TW, Shen F, Poultsides GA, Soubrane O, Martel G, Groot Koerkamp B, Guglielmi A, Itaru E, Pawlik TM. Defining Long-Term Survivors Following Resection of Intrahepatic Cholangiocarcinoma. J Gastrointest Surg 2017;21:1888-97. [DOI: 10.1007/s11605-017-3550-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
19 Song ZB, Yu Y, Zhang GP, Li SQ. Genomic Instability of Mutation-Derived Gene Prognostic Signatures for Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:728574. [PMID: 34676211 DOI: 10.3389/fcell.2021.728574] [Reference Citation Analysis]
20 Kim J, Kang W, Sinn DH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients. Clin Mol Hepatol 2020;26:516-28. [PMID: 32911589 DOI: 10.3350/cmh.2020.0016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
21 Nelson Hayes C, Zhang P, Chayama K; Department of Gastroenterology and Metabolism, Graduate School of Biomedical & Health Sciences, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Minami-ku, Hiroshima, Japan, Department of Gastroenterology and Metabolism, Graduate School of Biomedical & Health Sciences, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Minami-ku, Hiroshima, Japan, Department of Gastroenterology and Metabolism, Graduate School of Biomedical & Health Sciences, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Minami-ku, Hiroshima, Japan. The Role of Lipids in Hepatocellular Carcinoma. In: Tirnitz-parker JE, editor. Hepatocellular Carcinoma. Codon Publications; 2019. pp. 95-110. [DOI: 10.15586/hepatocellularcarcinoma.2019.ch5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
22 Le Linn Y, Guo Y, Koh YX, Chow PKH, Chan CY, Chung AYF, Ooi LLPJ, Goh BKP. Preoperative Predictors of Futile Resection of Intraabdominal Extrahepatic Metastases from Hepatocellular Carcinoma. World J Surg 2021;45:1144-51. [PMID: 33521877 DOI: 10.1007/s00268-020-05907-2] [Reference Citation Analysis]
23 Wang D, Liu J, Liu S, Li W. Identification of Crucial Genes Associated With Immune Cell Infiltration in Hepatocellular Carcinoma by Weighted Gene Co-expression Network Analysis. Front Genet 2020;11:342. [PMID: 32391055 DOI: 10.3389/fgene.2020.00342] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
24 Fang Y, Yang Y, Li N, Zhang XL, Huang HF. Emerging role of long noncoding RNAs in recurrent hepatocellular carcinoma. World J Clin Cases 2021; 9(32): 9699-9710 [PMID: 34877309 DOI: 10.12998/wjcc.v9.i32.9699] [Reference Citation Analysis]
25 Shimada S, Kamiyama T, Orimo T, Nagatsu A, Asahi Y, Sakamoto Y, Kamachi H, Taketomi A. Long-term prognostic factors of patients with hepatocellular carcinoma who survive over 10 years after hepatectomy. J Surg Oncol 2020;121:1209-17. [PMID: 32198765 DOI: 10.1002/jso.25910] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
26 Li F, Bai L, Li S, Chen Y, Xue X, Yu Z. Construction and evaluation of a prognosis lncRNA model for hepatocellular carcinoma. J Cell Biochem 2020. [PMID: 32348599 DOI: 10.1002/jcb.29608] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Lin J, Zhang F. Identification of Three Key Genes Associated with Hepatocellular Carcinoma Progression Based on Co-expression Analysis. Cell Biochem Biophys 2021. [PMID: 34406599 DOI: 10.1007/s12013-021-01028-2] [Reference Citation Analysis]
28 Moris D, Tsilimigras DI, Kostakis ID, Ntanasis-stathopoulos I, Shah KN, Felekouras E, Pawlik TM. Anatomic versus non-anatomic resection for hepatocellular carcinoma: A systematic review and meta-analysis. European Journal of Surgical Oncology 2018;44:927-38. [DOI: 10.1016/j.ejso.2018.04.018] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 9.0] [Reference Citation Analysis]
29 Lee DW, Kim HS, Han I. Actual long-term survival after resection of stage III soft tissue sarcoma. BMC Cancer 2021;21:21. [PMID: 33402132 DOI: 10.1186/s12885-020-07730-3] [Reference Citation Analysis]
30 Ho SY, Wang LC, Hsu CY, Liu PH, Hsia CY, Huang YH, Huo TI. Metavir Fibrosis Stage in Hepatitis C-Related Hepatocellular Carcinoma and Association with Noninvasive Liver Reserve Models. J Gastrointest Surg 2020;24:1860-2. [PMID: 32424685 DOI: 10.1007/s11605-020-04627-1] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Koda M, Tanaka S, Takemura S, Shinkawa H, Kinoshita M, Hamano G, Ito T, Kawada N, Shibata T, Kubo S. Long-Term Prognostic Factors after Hepatic Resection for Hepatitis C Virus-Related Hepatocellular Carcinoma, with a Special Reference to Viral Status. Liver Cancer 2018;7:261-76. [PMID: 30319984 DOI: 10.1159/000486902] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
32 Li ZL, Yan WT, Zhang J, Zhao YJ, Lau WY, Mao XH, Zeng YY, Zhou YH, Gu WM, Wang H, Chen TH, Han J, Xing H, Wu H, Li C, Wang MD, Wu MC, Shen F, Yang T. Identification of Actual 10-Year Survival After Hepatectomy of HBV-Related Hepatocellular Carcinoma: a Multicenter Study. J Gastrointest Surg 2019;23:288-96. [PMID: 30334177 DOI: 10.1007/s11605-018-4006-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
33 Sangineto M, Villani R, Cavallone F, Romano A, Loizzi D, Serviddio G. Lipid Metabolism in Development and Progression of Hepatocellular Carcinoma.Cancers (Basel). 2020;12. [PMID: 32486341 DOI: 10.3390/cancers12061419] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
34 Liu W, Liu Q, Zhang B, Lin Z, Li X, Yang X, Pu M, Zou R, He Z, Wang F, Dou K. The mRNA of TCTP functions as a sponge to maintain homeostasis of TCTP protein levels in hepatocellular carcinoma. Cell Death Dis 2020;11:974. [PMID: 33184257 DOI: 10.1038/s41419-020-03149-7] [Reference Citation Analysis]
35 Huang PY, Wang CC, Lin CC, Lu SN, Wang JH, Hung CH, Kee KM, Chen CH, Chen KD, Hu TH, Tsai MC. Predictive Effects of Inflammatory Scores in Patients with BCLC 0-A Hepatocellular Carcinoma after Hepatectomy. J Clin Med. 2019;8. [PMID: 31614976 DOI: 10.3390/jcm8101676] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
36 Han HH, Qiu YJ, Shi YY, Wen W, He XP, Dong LW, Tan YX, Long YT, Tian H, Wang HY. Glypican-3-targeted precision diagnosis of hepatocellular carcinoma on clinical sections with a supramolecular 2D imaging probe. Theranostics 2018;8:3268-74. [PMID: 29930728 DOI: 10.7150/thno.24711] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
37 Yang SY, Wang CC, Chen KD, Liu YW, Lin CC, Chuang CH, Tsai YC, Yao CC, Yen YH, Hsiao CC, Hu TH, Tsai MC. Statin use is associated with a lower risk of recurrence after curative resection in BCLC stage 0-A hepatocellular carcinoma. BMC Cancer 2021;21:70. [PMID: 33446127 DOI: 10.1186/s12885-021-07796-7] [Reference Citation Analysis]
38 Zhang B, Wang X, Deng J, Zheng H, Liu W, Chen S, Tian J, Wang F. p53-dependent upregulation of miR-16-2 by sanguinarine induces cell cycle arrest and apoptosis in hepatocellular carcinoma. Cancer Lett 2019;459:50-8. [PMID: 31163195 DOI: 10.1016/j.canlet.2019.05.042] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
39 Linn YL, Chee MY, Koh YX, Teo JY, Cheow PC, Chow PKH, Chan CY, Chung AYF, Ooi LLPJ, Goh BKP. Actual 10-year survivors and 10-year recurrence free survivors after primary liver resection for hepatocellular carcinoma in the 21st century: A single institution contemporary experience. J Surg Oncol 2021;123:214-21. [PMID: 33095920 DOI: 10.1002/jso.26259] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Sun Y, Wu L, Zhong Y, Zhou K, Hou Y, Wang Z, Zhang Z, Xie J, Wang C, Chen D, Huang Y, Wei X, Shi Y, Zhao Z, Li Y, Guo Z, Yu Q, Xu L, Volpe G, Qiu S, Zhou J, Ward C, Sun H, Yin Y, Xu X, Wang X, Esteban MA, Yang H, Wang J, Dean M, Zhang Y, Liu S, Yang X, Fan J. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. Cell 2021;184:404-421.e16. [PMID: 33357445 DOI: 10.1016/j.cell.2020.11.041] [Cited by in Crossref: 20] [Cited by in F6Publishing: 34] [Article Influence: 10.0] [Reference Citation Analysis]
41 Chen ZX, Jian ZW, Wu XW, Wang JC, Peng JY, Lao XM. Clinical conditions and treatment requirements for long-term survival among hepatitis B-related hepatocellular carcinoma initially treated with chemoembolization. Cancer Med 2019;8:5097-107. [PMID: 31313476 DOI: 10.1002/cam4.2380] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
42 Zhou KQ, Sun YF, Cheng JW, Du M, Ji Y, Wang PX, Hu B, Guo W, Gao Y, Yin Y, Huang JF, Zhou J, Fan J, Yang XR. Effect of surgical margin on recurrence based on preoperative circulating tumor cell status in hepatocellular carcinoma. EBioMedicine 2020;62:103107. [PMID: 33181461 DOI: 10.1016/j.ebiom.2020.103107] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Zheng J, Seier K, Gonen M, Balachandran VP, Kingham TP, D'Angelica MI, Allen PJ, Jarnagin WR, DeMatteo RP. Utility of Serum Inflammatory Markers for Predicting Microvascular Invasion and Survival for Patients with Hepatocellular Carcinoma. Ann Surg Oncol 2017;24:3706-14. [PMID: 28840521 DOI: 10.1245/s10434-017-6060-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
44 Fung AKY, Cheng NMY, Chong CCN, Lee KF, Wong J, Cheung SYS, Lok HT, Lai PBS, Ng KKC. Single-center experience on actual mid-term (≥5 years) and long-term (≥10 years) survival outcome in patients with hepatocellular carcinoma after curative hepatectomy: A bimodal distribution. Medicine (Baltimore) 2020;99:e23358. [PMID: 33235106 DOI: 10.1097/MD.0000000000023358] [Reference Citation Analysis]
45 Best J, Schotten C, Lohmann G, Gerken G, Dechêne A. Tivantinib for the treatment of hepatocellular carcinoma. Expert Opinion on Pharmacotherapy 2017;18:727-33. [DOI: 10.1080/14656566.2017.1316376] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
46 Nakagawa H, Hayata Y, Kawamura S, Yamada T, Fujiwara N, Koike K. Lipid Metabolic Reprogramming in Hepatocellular Carcinoma. Cancers (Basel) 2018;10:E447. [PMID: 30445800 DOI: 10.3390/cancers10110447] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 13.5] [Reference Citation Analysis]